The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Takeda / Shire)

In Takeda/Shire [1], the European Commission has conditionally cleared a concentration between two drug manufacturers by accepting a divestment remedy in the context of the Phase I Investigation. The planned merger operation Takeda and Shire are two major global pharmaceutical companies headquartered in Japan and Jersey, respectively. Their product portfolios are largely complementary with Shire focused on rare genetic diseases and immunology and Takeda on vaccines, oncology and gastroenterology. By the notified merger, Takeda intended to acquire the sole control over Shire. The decision of the Commission Though the proposed merger might potentially affect several pharmaceutical markets, the Commission had concerns that the transaction would harm competition only in the market for

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Desogus Law Office (Cagliari)

Quotation

Michele Giannino, The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Takeda / Shire), 20 November 2018, e-Competitions Bulletin November 2018, Art. N° 89622

Visites 365

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues